<DOC>
	<DOCNO>NCT02039401</DOCNO>
	<brief_summary>The purpose study determine safety tolerability intramuscular injection VM202 different injection sit people amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>Safety Study VM202 Treat Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Age ≥ 21 year , &lt; = 75 year Subjects diagnose : clinically definite ALS , clinically probable ALS , clinically probablelaboratory support ALS specify revise El Escorial / Airlie House diagnostic criterion Onset ALS &lt; 2 year Screening Forced Vital Capacity ( FVC ) ≥ 60 % predict Revised Amyotrophic Lateral Sclerosis Functional Rating Scale ( ALSFRSR ) ≥ 30 Not take riluzole , stable dose least thirty day prior Screening ( define note toxicity ) Able willing give inform consent If female childbearing potential , negative urine pregnancy test Screening use acceptable method birth control study . Neurological symptom ( ) due vitamin B12 deficiency Requires tracheotomy ventilation noninvasive ventilation &gt; 16 hour / day Comorbidities Parkinson 's disease , schizophrenia , renal failure , severe complication , Investigator 's opinion , compromise safety patient confound interpretation data collect study Other neuromuscular disease Inflammatory disorder blood vessel ( inflammatory angiopathy , Buerger 's disease ) Active infection Chronic inflammatory disease ( e.g. , Crohn 's disease , rheumatoid arthritis ) Positive HIV HTLV Screening Active Hepatitis B C determine Hepatitis B core antibody ( HBcAb ) , antibody Hepatitis B surface antigen ( IgG IgM ; HBsAb ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( AntiHCV ) Screening Subjects know immunosuppression currently receive immunosuppressive drug , chemotherapy radiation therapy Stroke myocardial infarction within last 3 month Patients recent history ( &lt; 5 year ) malignant neoplasm except basal cell carcinoma squamous cell carcinoma skin ( excised evidence recurrence ) ; Subjects require &gt; 81 mg daily acetylsalicylic acid ; subject may enrol willing/able switch ≤ 81 mg daily acetylsalicylic acid another medication Subjects require regular COX2 inhibitor drug ( ) nonspecific COX1/COX2 inhibiting drug , high dose steroid ( except inhale steroid ) ; subject may enrol willing/able undergo medication washout prior first dose refrain take drug duration study Have use investigational drug within 30 day Screening Pregnant currently lactate Major psychiatric disorder past 6 month Known drug alcohol dependence factor interfere study conduct interpretation result opinion Investigator suitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>neurodegenerative disease</keyword>
</DOC>